- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Philips ultrasound upgrade targets breast imaging
Enhancements in breast imaging mark the latest ultrasound upgrade from Philips Healthcare. Tissue aberration correction technology and algorithms built into the Vision 2009 upgrade for its iU22 radiological flagship are part of an integrated effort to better define tissue in fatty breasts, according to the company. An enabling technology is the Philips PureWave transducer and its coded beamformer, which have been present on earlier technologies.
Enhancements in breast imaging mark the latest ultrasound upgrade from Philips Healthcare. Tissue aberration correction technology and algorithms built into the Vision 2009 upgrade for its iU22 radiological flagship are part of an integrated effort to better define tissue in fatty breasts, according to the company. An enabling technology is the Philips PureWave transducer and its coded beamformer, which have been present on earlier technologies.
Tissue aberration correction, which was devised initially to look at obese patients, compensates for speed of sound variations of dense tissue, improving detail resolution and conspicuity of lesion details. Another major addition of Vision 2009 is the VL13-5 high-frequency volume linear transducer, which is clinically optimized for breast, thyroid, carotid, and general applications.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
Mammography-Based AI Abnormality Scoring May Improve Prediction of Invasive Upgrade of DCIS
April 9th 2024Emerging research suggests that an artificial intelligence (AI) score of 75 or greater for mammography abnormalities more than doubles the likelihood of invasive upgrade of ductal carcinoma in situ (DCIS) diagnosed with percutaneous biopsy.
